

**NBTXR3-ENHANCED PROTON BEAM IMMUNORADIOTHERAPY RESHAPES TUMOR IMMUNE MICROENVIRONMENT AND IMPROVES ABCOPAL EFFECT IN AN ANTI-PD1-RESISTANT LUNG CANCER**

<sup>1</sup>Yun Hu\*, <sup>2</sup>Sebastien Paris, <sup>1</sup>Narayan Sahoo, <sup>1</sup>Genevieve Bertolet, <sup>1</sup>Qi Wang, <sup>1</sup>Qianxia Wang, <sup>1</sup>Hampartsoum Barsoumian, <sup>2</sup>Jordan SILVA, <sup>1</sup>Ailing Huang, <sup>1</sup>Claudia Kettlun Leyton, <sup>1</sup>Tiffany Voss, <sup>1</sup>Ethan Hsu, <sup>1</sup>Fatemeh Masrourpour, <sup>1</sup>Carola Leuschner, <sup>1</sup>Nahum Puebla Osorio, <sup>1</sup>Quynh Nguyen, <sup>1</sup>Saumil Gandhi, <sup>1</sup>Jing Wang, <sup>1</sup>Maria Cortez, <sup>1</sup>James Welsh. <sup>1</sup>MD Anderson Cancer Center, Houston, TX, United States; <sup>2</sup>Nanobiotix, Paris, France

**Background** Proton beam therapy (PBT) has frequently yielded superior results to conventional X-ray therapy. However, combination of PBT with checkpoint inhibitors is rarely reported for treating metastatic cancers. NBTXR3 is a radioenhancer with immunomodulatory capacities able to restore efficacy of anti-PD1 (aPD1) in a model resistant to this treatment with conventional X-ray therapy. Therefore, we hypothesized that addition of NBTXR3 to localized PBT combined with aPD1 could enhance the systemic antitumor immune response in aPD1-resistant lung cancer in mice.

**Methods** Five groups of 8 mice each were inoculated with  $5 \times 10^4$  aPD1-resistant 344SQR murine lung cancer cells in each hind leg, 4 days apart, to establish 'primary' (right, to-be-irradiated) and 'secondary' (left, not-to-be-irradiated) tumors. aPD1 (200  $\mu$ g) was intraperitoneally administered on days 7, 10, 14, 21, 28, 35, and 42. Primary tumors were intratumorally injected with NBTXR3 on day 7, followed by 12 Gy PBT on days of 8 and 9 (24 Gy total). The immune microenvironment of both irradiated and unirradiated tumors was analyzed through NanoString and single cell sequencing. On day 76, the right flank of the survivor mice treated with NBTXR3+PBT+aPD1 was rechallenged with  $5 \times 10^4$  344SQR cells.

**Results** The therapies of PBT, PBT+aPD1, NBTXR3+PBT, and NBTXR3+PBT+aPD1 each resulted in significantly delayed growth in both primary and secondary tumors relative to control. In addition, adding NBTXR3 to both PBT and PBT+aPD1 significantly retarded the progress of the two tumors. Remarkably, the combination therapy of NBTXR3+PBT+aPD1 achieved 37.5% survival rate and the lowest number of lung metastases. Moreover, the survivor mice maintained potent antitumor immunological memory, effectively rejecting tumor re-challenge. NanoString analysis of immune-related genes revealed that the triple therapy (NBTXR3+PBT+aPD1) significantly upregulated the activities of a wide range of antitumor immune pathways in the two tumors. Single cell analysis demonstrated that both PBT+aPD1 and NBTXR3+PBT+aPD1 increased tumor infiltration by NKT cells, innate lymphoid cells, and CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, and gamma delta T cells, as well as promoted cytotoxic lymphocyte activation. Lastly, PBT-mediated immunoradiotherapy enriched specific TCR repertoires that may target tumor antigens.

**Conclusions** PBT combined with aPD1 was able to potently activate systemic antitumor immunity and effectively control both irradiated and unirradiated tumors. In this context, the addition of NBTXR3 to PBT+aPD1 significantly improved treatment efficacy through modulating the tumor immune microenvironment.

**Ethics Approval** All mouse studies were approved by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center.

<http://dx.doi.org/10.1136/jitc-2022-SITC2022.0869>